Zentek (ZTEK)
NASDAQ:ZTEK
Want to see ZTEK full AI Analyst Report?
ZTEK Stock Chart & Stats
$0.69
-$0.05(-4.63%)
At close: 4:00 PM EST
$0.69
-$0.05(-4.63%)
Day’s Range― - ―
52-Week Range$0.40 - $1.62
Previous CloseN/A
Volume66.53K
Average Volume (3M)63.87K
Market Cap
$67.81M
Enterprise Value$93.66M
Total Cash (Recent Filing)$1.80M
Total Debt (Recent Filing)$1.90M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding107,543,560
10 Day Avg. Volume35,879
30 Day Avg. Volume63,873
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)11.24
Price to Sales (P/S)190.02
P/FCF Ratio-26.38
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue99.34
Enterprise Value/Gross Profit-132.83
Enterprise Value/Ebitda-11.92
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthModest leverage and low debt provide durable financial flexibility; meaningful assets relative to revenue give runway for continued R&D or commercialization investments without immediate refinancing. This strengthens strategic optionality and limits solvency risk over the next 2–6 months.
Revenue Growth TrajectoryVery strong reported revenue growth signals early commercial traction from a low base; sustained top-line expansion, if continued, supports scale-up of operations and improves the chance of moving toward break-even economics. Growth momentum is a durable indicator of market adoption potential.
IP And Commercialization StrategyA business model built on R&D, intellectual property and multiple routes to market (manufacturing, licensing, partnerships) creates structural optionality: it enables leverageable revenue streams, potential high-margin licensing, and diversified paths to commercialization that persist beyond short-term cycles.
Bears Say
Tiny Revenue Base & Negative MarginsRevenue remains extremely small while gross margin has turned negative, indicating the business is not yet at commercial scale. Negative unit economics pressure profitability and make sustainable operations dependent on either rapid margin improvement or substantial external capital over the medium term.
Persistent Cash BurnConsistent negative operating and free cash flow mean the company is not self-funding and will likely need financing to sustain R&D and commercialization. Ongoing cash burn increases dilution risk, constrains strategic choices, and creates dependency on capital markets or partners over the coming months.
Large Operating Losses & Weak ReturnsSubstantial operating losses relative to a tiny revenue base lead to very negative ROE and erode shareholder equity over time. Persistent losses reduce bargaining power with partners and investors and make it harder to fund scaling without dilutive raises or meaningful margin improvement.
Zentek News
ZTEK FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was $0.40 and its highest was $1.62 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is $67.81M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Jul 01, 2026 which is in 37 days.
How were Zentek’s earnings last quarter?
Zentek released its earnings results on Feb 17, 2026. The company reported -$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.017.
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Overvalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 107,543,560 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Zentek reported an EPS of -$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.674%.
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in ZTEK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 154.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.65%
12-Months-Change
Fundamentals
Return on Equity
-61.26%
Trailing 12-Months
Asset Growth
-4.13%
Trailing 12-Months
Company Description
Zentek
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
―
Sona Nanotech Inc
―
Ownership Overview
1.11% Insiders
0.05% Mutual Funds
0.99% Other Institutional Investors
97.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---